{"name":"Clementia Pharmaceuticals Inc.","slug":"clementia-pharmaceuticals-inc","ticker":"","exchange":"","domain":"clementia.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Palovarotene dose level 2","genericName":"Palovarotene dose level 2","slug":"palovarotene-dose-level-2","indication":"Other","status":"phase_2"},{"name":"Palovarotene dose level 4","genericName":"Palovarotene dose level 4","slug":"palovarotene-dose-level-4","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Palovarotene dose level 2","genericName":"Palovarotene dose level 2","slug":"palovarotene-dose-level-2","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Palovarotene dose level 4","genericName":"Palovarotene dose level 4","slug":"palovarotene-dose-level-4","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxQaThqSGxDa216LTdzWVJHU3pQVmIzM01KZEtZOHgtQkhzWWtmaENkYWlPZ21VdGJfR1Y0bDd0Ui1VQWZELWdYdXJTZWlBa0lzcWR1SVdKaE9YbUotMVlPaVp1Y3I1SzV2NDVCbXhlM3pJWXQ0OXJ2QXl3ai1SZVpQSlhtWlpJaWV6endnWENESHFvdFI1YldhM01XQXplR2tmUXNVUk1KaV9lT1JCeHU2djI2blgxX1lubnU2V3RqWldlbGQ0MlZMUER1UmFtc1B5VlE5cl9wYjhNOWtFZy1SVEE4NF9wajM1eThrVTRvdE5EU09IcC0zYw?oc=5","date":"2024-05-06","type":"pipeline","source":"PR Newswire","summary":"Congruence Therapeutics Appoints Experienced Drug Developer Michael D. Harvey, Ph.D. as Chief Development Officer - PR Newswire","headline":"Congruence Therapeutics Appoints Experienced Drug Developer Michael D. Harvey, Ph.D. as Chief Development Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQMXI5YXNzemJuVXdEY0VGaHNiajNabG5EQ3dUSGhLU1drYlZSLS05aFJRc0NNY0lBTEFVR1Z0dkFtSWxqWC10cjc2SzViYlEwZkx2VDh3bWpjaU5SZHFjak8xbEg3eVNiUFN3T216NUItdzU1T04zR2FNbEpUVkhCMllUc2NzeVU2T2hqY0syVzdTcVk?oc=5","date":"2023-06-16","type":"regulatory","source":"The Globe and Mail","summary":"Bellus shareholders approve US$2-billion takeover by GSK; deal set to close this month - The Globe and Mail","headline":"Bellus shareholders approve US$2-billion takeover by GSK; deal set to close this month","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQT3pIVU84TERpUEFXX0ZMN1VSRUYwZGdRc2lJMUdpMHYtTDhFNnFiRGRTdHRfZUpfa191eXhBUlA2M20xM09YdHhqelNEUnFFaGdZTTJBZ1ZSc3BIMDJlZnVJbkQ5ZlZPNHV3akRMWXN6a1dnQXA4aTI0NW5oU1oxNGcwMWphZFR6bHl0SzdqVWlFQQ?oc=5","date":"2023-06-12","type":"deal","source":"The Globe and Mail","summary":"Novartis buys Chinook for US$3.2-billion, latest in string of big exits for Canadian biotechs - The Globe and Mail","headline":"Novartis buys Chinook for US$3.2-billion, latest in string of big exits for Canadian biotechs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPOHNVdW93b0NpX1JRbXNnOFJyRUplZG50Y0liZmRvM0ZlRHN5RkZUaXNUVHFaQ29UY3ZJR0RER1pIU3BWcGpqdTh1ZWxZc3ZqeGota3N1TjlqS1hLaEV5TjA2cWtkLVRiQ0lXNE04VnRScmlkTnhBVzdXZHJYODdqbzZaaE5XUQ?oc=5","date":"2023-04-18","type":"pipeline","source":"The Globe and Mail","summary":"GSK’s $2-billion purchase of Bellus delivers second big exit for Montreal’s Bellini family - The Globe and Mail","headline":"GSK’s $2-billion purchase of Bellus delivers second big exit for Montreal’s Bellini family","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPaThLRDNLaWxEdDB1ZXVhMUJuZi12dVREX2JDWmVBWHVUY05ZRWJrbTFoZ1hTRGRTU0RvVGtBbWFoeUhxcHdnbERZb2d6VFE4U1pJdDIyT1pxdVlWeXB3OS1lc19iUUtZNDJvM0dlYU96VkFjc2c0aExhZlZWSnUxWmgweXo1blBqaE1OaVB0SG1ueWtjSmIxa2ItcFhkY3BHajNJUlUybUlJb0diRXd3Z2ZidkEwbk8wSEtCRW9wb3p0cGM?oc=5","date":"2023-03-02","type":"pipeline","source":"Ipsen","summary":"Acquisition of Albireo has been completed | Ipsen Global - Ipsen","headline":"Acquisition of Albireo has been completed | Ipsen Global","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxQMVhtVmVmRVBjMENlZmFYc1VlWTduNHoxR2ZiRWZnRFA3M1dXVU50V0NwTGhQbDJiT3o3QzR3c05HZWZBTnI2dnBNVnBhRlg4dWhDX0ZwclFjb2ozZkQ4MV81d2RoTmgyc3RvX1pJZUlXRDBlb3lseGkzLUNVR3FSY3NwM095N0xkRmhOTllRNFpNT1B6Wjc4eVhKYjA2ZkIzc0hyOUQwdHRITmlFQWNWTVZZc0VBYkduUVZrbUV6eTcydFRURjhyYUtBS29CbkFXcmpXYXRTT2pLalVzVU9uQnVDeWg?oc=5","date":"2023-01-09","type":"deal","source":"Ipsen","summary":"Ipsen to Acquire Albireo - Growth in Rare Disease | Ipsen Global - Ipsen","headline":"Ipsen to Acquire Albireo - Growth in Rare Disease | Ipsen Global","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQWlBpcEE1ZXRVaFFYUUk1NW1TQ3ZQa2ZfcTJoengwc0Z6aDJIWWo1RExqaGFPbDNGWXJ3X3ZPYnFYTVJqZnd2bFB2Znk2SXBjcmxPenNKdzgtRGdDZy1MdzZmWEF1c3g0ajhzbEg5NmtpTkh3Y3UzNFBfZXVsejVaNlRyM1lQb2J4VndfV1RBU3Q1U2V1ZktJdy1MaEJGUU8xOHl6ZGF5QmR3X2NzMjBHUW4ydHVlc2Mzc3ZB?oc=5","date":"2022-02-08","type":"pipeline","source":"The Globe and Mail","summary":"Montreal biotech startup Congruence raises $50-million to focus on rare disease drugs - The Globe and Mail","headline":"Montreal biotech startup Congruence raises $50-million to focus on rare disease drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNenBoS1R6MzRnU25tQ09RU00zbWVWTU82MXg3cEsxREJLWDk3aW16Wm9RQnlLZmM3ODhGaV9rWmFYNmtfQmp4NElXbm1kT1hpT0ZkU1dfTENTdmxjNTlzSGVJdVBXWklEOUJ6Nk0xY01BVGkxNzA1R0RvelRpX1hGbVIxV0M0Ym5rcEN2dHc2cE9jN3JfVkxod3cwUlRUYmZkMEVpYi13ZFY5ZFd0UVc2MGF4TjFNcHE4WXZQSmxqOG9Fdw?oc=5","date":"2020-08-19","type":"regulatory","source":"24/7 Wall St.","summary":"What This FDA Response Means for BioMarin’s Gene Therapy for Hemophilia - 24/7 Wall St.","headline":"What This FDA Response Means for BioMarin’s Gene Therapy for Hemophilia - 24/7 Wall St.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQNG5zYlpUdWhYbk9RRWNfV012RVVURE9KRFJDdnlSVFpRV3Uxb2pyUDF4X2pTQ1ZfdlRmWHNrMEhibnpybXNzeFVxMVdDNmhUbzZ0MjRJUHFFYlFzdHBVejBUckhVeWdsOGphUEItUTV6TDREak15ZzVMcUlOYWwxajZyLU92VnJuX3Fla0Fja2pmN21TMElISmpWTVBvdjB3bmVUWXFpa2xiMmoyMEY2YW83MA?oc=5","date":"2019-02-25","type":"pipeline","source":"The Globe and Mail","summary":"For Clementia Pharmaceuticals founder, US$1-billion takeover of Montreal biotech is ‘bittersweet’ outcome - The Globe and Mail","headline":"For Clementia Pharmaceuticals founder, US$1-billion takeover of Montreal biotech is ‘bittersweet’ outcome","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQbFNtcmZpWUxwRXY4M3ZDS2Zvbkx6cFNvcHdTSW5URDh1S05MQXB6R21aclU1WlJVaHd3QWt6R3Bib3ljWnVkZU1zR0V1d0pVQ1hUV1ctbEdscHR3anBhRmI2dEZBX3ViVFlKRkQzRjI2Q3VCeUtqNTNVckRNcFRFWVNRZmszdjJTTWpVZDhaNjRHeUJpR0wzbVlQYzFYUUJUUEoyUUY4REQ0TWNqU3Rn?oc=5","date":"2017-08-02","type":"pipeline","source":"PR Newswire","summary":"Clementia Announces Pricing of Initial Public Offering - PR Newswire","headline":"Clementia Announces Pricing of Initial Public Offering","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}